Skip to main content
Journal cover image

Biosimilars in rheumatology: understanding the rigor of their development.

Publication ,  Journal Article
Goel, N; Chance, K
Published in: Rheumatology (Oxford)
February 2017

This article examines the current landscape of biosimilar development in rheumatology. As misperceptions about biosimilars exist regarding their comparability to the reference products for clinical use, we review the development paradigm with the goal of improving rheumatologists' understanding of the rigor with which biosimilars are developed. With an emphasis on European Union and US markets, it gives an overview of some of the challenges and issues related to biosimilar development that need to be considered by rheumatologists in this increasingly growing therapeutic space.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

February 2017

Volume

56

Issue

2

Start / End Page

187 / 197

Location

England

Related Subject Headings

  • United States
  • Rheumatology
  • Rheumatic Diseases
  • Humans
  • European Union
  • Drug Discovery
  • Biosimilar Pharmaceuticals
  • Arthritis & Rheumatology
  • Antirheumatic Agents
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goel, N., & Chance, K. (2017). Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford), 56(2), 187–197. https://doi.org/10.1093/rheumatology/kew206
Goel, Niti, and Kamali Chance. “Biosimilars in rheumatology: understanding the rigor of their development.Rheumatology (Oxford) 56, no. 2 (February 2017): 187–97. https://doi.org/10.1093/rheumatology/kew206.
Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford). 2017 Feb;56(2):187–97.
Goel, Niti, and Kamali Chance. “Biosimilars in rheumatology: understanding the rigor of their development.Rheumatology (Oxford), vol. 56, no. 2, Feb. 2017, pp. 187–97. Pubmed, doi:10.1093/rheumatology/kew206.
Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford). 2017 Feb;56(2):187–197.
Journal cover image

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

February 2017

Volume

56

Issue

2

Start / End Page

187 / 197

Location

England

Related Subject Headings

  • United States
  • Rheumatology
  • Rheumatic Diseases
  • Humans
  • European Union
  • Drug Discovery
  • Biosimilar Pharmaceuticals
  • Arthritis & Rheumatology
  • Antirheumatic Agents
  • 3204 Immunology